Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics Plc (AKTX) is a clinical-stage biopharmaceutical company advancing innovative treatments for rare autoimmune and inflammatory diseases. This page provides investors and industry observers with timely updates on the company’s clinical developments, regulatory milestones, and strategic initiatives.
Access comprehensive coverage of AKTX’s progress, including press releases on trial results, FDA designations, and partnership announcements. Our curated news collection focuses on developments related to coversin, nomacopan, and other pipeline candidates targeting complement-mediated disorders.
Key updates include progress in treating conditions like HSCT-TMA and Geographic Atrophy, manufacturing partnerships, and scientific presentations. All content is verified from primary sources to ensure accuracy for investment research and market analysis.
Bookmark this page for centralized access to AKTX’s latest developments in complement system therapeutics. Check regularly for objective updates on clinical advancements and corporate announcements relevant to biopharmaceutical investors.
Akari Therapeutics, Plc (Nasdaq: AKTX) announced it has been granted an additional 180-day compliance period by Nasdaq, extending the deadline to regain compliance with the minimum bid price requirement until October 23, 2023. To maintain its listing, Akari must keep a minimum closing bid price of $1.00 per share for at least ten consecutive business days. There is no immediate impact on the company’s Nasdaq listing, and its American Depository Shares will continue to be traded. Akari is focused on developing advanced therapies for autoimmune diseases, with lead investigational asset nomacopan undergoing Phase 3 trials for pediatric HSCT-TMA. The company holds Orphan Drug and Fast Track designations from the FDA for this treatment.
FAQ
What is the current stock price of Akari Therapeutics Plc (AKTX)?
What is the market cap of Akari Therapeutics Plc (AKTX)?
